The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Ganguly, 1976, Spironolactone therapy in primary aldosteronism: diagnostic and therapeutic implications
Cited by
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Self-citation2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., et al. (2017) · Pediatrics · doi:10.1542/peds.2017-1904 · Cited by 3,651
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citationDiretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. D. M., Machado, C. A., Poli-de-Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,068
2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127
Self-citationMonticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30319-4 · Cited by 1,072
“The Endocrine Society has in 2016 updated their clinical practice guidelines regarding screening, diagnosing, and treatment of primary aldosteronism (9).”
BackgroundWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000597 · Cited by 902
Self-citationFassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Williams, T. A., Lenders, J. W. M., Mulatero, P., Burrello, J., Rottenkolber, M., Adolf, C., Satoh, F., Amar, L., Quinkler, M., Deinum, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30135-3 · Cited by 969
Self-citationOlsen, M. H., Angell, S. Y., Asma, S., Boutouyrie, P., Burger, D., Chirinos, J. A., Damasceno, A., Delles, C., Gimenez-Roqueplo, A.-P., Hering, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31134-5 · Cited by 939
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.005 · Cited by 920
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.06.010 · Cited by 947
Self-citationPrevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice
Monticone, S., Burrello, J., Tizzani, D., Bertello, C., Viola, A., Buffolo, F., Gabetti, L., Mengozzi, G., Williams, T. A., Rabbia, F., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.052 · Cited by 882
“The ARR is the most reliable means to screen for PA, but a unique cutoff is difficult to define because of the wide variability of laboratory assays and population-specific characteristics (4,5).”
BackgroundMethodInfluentialFassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
“61-63 Rapid onset and progression of hirsutism or virilization is a clinical indicator for an androgen-producing tumor and However, for clinical management, the presence of co-morbidities potentially attributable to cortisol excess (Table 5), age, and the general condition of the patient are major…”
BackgroundInfluentialThe Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study
Brown, J. M., Siddiqui, M., Calhoun, D. A., Carey, R. M., Hopkins, P. N., Williams, G. H., & Vaidya, A. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0065 · Cited by 649
“This prevalence could be substantially modulated with the application of more liberal or conservative diagnostic thresholds (7).”
BackgroundMethodInfluentialSelf-citationHundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30367-4 · Cited by 677
“(2, 3) It is estimated that 4–19% of patients with hypertension,(3–5) and 3–14% of patients with normotension,(6–8) may have PA.”
BackgroundResultInfluentialNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
“The plasma aldosterone-to-renin ratio in patients with primary hyperaldosteronism is usually greater than 30.(87) Confir-”
BackgroundClase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf284 · Cited by 355
Self-citationKäyser, S. C., Dekkers, T., Groenewoud, H. J., van der Wilt, G. J., Carel Bakx, J., van der Wel, M. C., Hermus, A. R., Lenders, J. W., & Deinum, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1472 · Cited by 398
Hypokalemia: a clinical update
Kardalas, E., Paschou, S. A., Anagnostis, P., Muscogiuri, G., Siasos, G., & Vryonidou, A. (2018) · Endocrine Connections · doi:10.1530/ec-18-0109 · Cited by 362
Diagnosis and treatment of primary aldosteronism
Reincke, M., Bancos, I., Mulatero, P., Scholl, U. I., Stowasser, M., & Williams, T. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00210-2 · Cited by 354
Self-citationSherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347
“Clinical guidelines recommend screening for PA in every (AI) patient with hypertension or hypokalemia (283,284).”
BackgroundMethodWilliams, B., MacDonald, T. M., Morant, S. V., Webb, D. J., Sever, P., McInnes, G. T., Ford, I., Cruickshank, J. K., Caulfield, M. J., Padmanabhan, S., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30071-8 · Cited by 347
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 213
Mulatero, P., Monticone, S., Deinum, J., Amar, L., Prejbisz, A., Zennaro, M.-C., Beuschlein, F., Rossi, G. P., Nishikawa, T., Morganti, A., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002510 · Cited by 317
“For greater than 30 ng/dl and unilateral adenoma (>10 mm) with normal contralateral adren has been suggested [11], based on three studies [50–52].”
BackgroundMethodInfluentialDiagnosis and treatment of primary aldosteronism: practical clinical perspectives
Young, W. F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12831 · Cited by 325
Self-citationInternational Histopathology Consensus for Unilateral Primary Aldosteronism
Williams, T. A., Gomez-Sanchez, C. E., Rainey, W. E., Giordano, T. J., Lam, A. K., Marker, A., Mete, O., Yamazaki, Y., Zerbini, M. C. N., Beuschlein, F., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa484 · Cited by 311
Self-citationVaidya, A., Mulatero, P., Baudrand, R., & Adler, G. K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00139 · Cited by 299
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
Arlt, W., Lang, K., Sitch, A. J., Dietz, A. S., Rhayem, Y., Bancos, I., Feuchtinger, A., Chortis, V., Gilligan, L. C., Ludwig, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93136 · Cited by 281
“Current diagnostic work-up in primary aldosteronism, however, does not include assessment for hypercortisolism (1).”
Self-citationJones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
CLCN2 chloride channel mutations in familial hyperaldosteronism type II
Scholl, U. I., Stölting, G., Schewe, J., Thiel, A., Tan, H., Nelson-Williams, C., Vichot, A. A., Jin, S. C., Loring, E., Untiet, V., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0048-5 · Cited by 266
“The intracellular solution contained (in mM): NaCl (73), MgCl2 (1), NaGluconate (42), EGTA (5), HEPES (10) and MgATP (1) at pH 7.4.”
InfluentialSelf-citationRenal Outcomes in Medically and Surgically Treated Primary Aldosteronism
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11568 · Cited by 245
Primary Aldosteronism in Patients in China With Recently Detected Hypertension
Xu, Z., Yang, J., Hu, J., Song, Y., He, W., Luo, T., Cheng, Q., Ma, L., Luo, R., Fuller, P. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.052 · Cited by 237
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2003 · Cited by 240
Naruse, M., Katabami, T., Shibata, H., Sone, M., Takahashi, K., Tanabe, A., Izawa, S., Ichijo, T., Otsuki, M., Omura, M., et al. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0508 · Cited by 217
Self-citationGuideline-Driven Management of Hypertension: An Evidence-Based Update
Carey, R. M., Wright, J. T., Taler, S. J., & Whelton, P. K. (2021) · Circulation Research · doi:10.1161/circresaha.121.318083 · Cited by 190
Self-citationA gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism
Fernandes-Rosa, F. L., Daniil, G., Orozco, I. J., Göppner, C., El Zein, R., Jain, V., Boulkroun, S., Jeunemaitre, X., Amar, L., Lefebvre, H., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0053-8 · Cited by 215
The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study
Brown, J. M., Robinson-Cohen, C., Luque-Fernandez, M. A., Allison, M. A., Baudrand, R., Ix, J. H., Kestenbaum, B., de Boer, I. H., & Vaidya, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0882 · Cited by 221
“Although the aldosterone-torenin ratio is a highly sensitive tool for detecting PA in severe hypertensive or hypokalemic populations (20), some studies have shown that when confirmatory testing for PA is applied to populations with no obvious clinical phenotype for PA or MR overactivation, a surprisingly high prevalen…”
InfluentialCellular and Genetic Causes of Idiopathic Hyperaldosteronism
Omata, K., Satoh, F., Morimoto, R., Ito, S., Yamazaki, Y., Nakamura, Y., Anand, S. K., Guo, Z., Stowasser, M., Sasano, H., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11086 · Cited by 209
Self-citationContinuum of Renin-Independent Aldosteronism in Normotension
Baudrand, R., Guarda, F. J., Fardella, C., Hundemer, G., Brown, J., Williams, G., & Vaidya, A. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08952 · Cited by 202
“However, emerging research suggests that the spectrum of renin-independent aldosteronism may involve a more extensive continuum.4 For example, when PA screening and confirmatory testing were conducted indiscriminately in a large population of mild-to-moderate essential hypertensives, 10% of patients were confirmed to…”
InfluentialPrimary aldosteronism — a multidimensional syndrome
Turcu, A. F., Yang, J., & Vaidya, A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00730-2 · Cited by 189
Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans
Nanba, K., Omata, K., Else, T., Beck, P. C. C., Nanba, A. T., Turcu, A. F., Miller, B. S., Giordano, T. J., Tomlins, S. A., & Rainey, W. E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01004 · Cited by 181
“The clinical diagnosis of PA was made according to available institutional guidelines at the time or the Endocrine Society’s clinical practice guideline (22).”
MethodApproach to the Patient With Adrenal Incidentaloma
Bancos, I., & Prete, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab512 · Cited by 201
Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term
Rossi, G. P., Maiolino, G., Flego, A., Belfiore, A., Bernini, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10596 · Cited by 194
“Treatment-naive patients were investigated with no antihypertensive drugs; those already treated underwent screening after switching to calcium channel blockers or doxazosin, or a combination of the two agents(19,20).”
Self-citationGenetic Characteristics of Aldosterone-Producing Adenomas in Blacks
Nanba, K., Omata, K., Gomez-Sanchez, C. E., Stratakis, C. A., Demidowich, A. P., Suzuki, M., Thompson, L. D. R., Cohen, D. L., Luther, J. M., Gellert, L., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12070 · Cited by 175
Cohen, J. B., Cohen, D. L., Herman, D. S., Leppert, J. T., Byrd, J. B., & Bhalla, V. (2021) · Annals of Internal Medicine · doi:10.7326/m20-4873 · Cited by 173
“Because of the detailed information in the VHA electronic health record, we were able to carefully identify patients with new-onset apparent treatment-resistant hypertension who were followed at the VHA for their primary care since the time of incident hypertension diagnosis, thus minimizing misclassification of testi…”
BackgroundInfluentialGuidelines for primary aldosteronism: uptake by primary care physicians in Europe
Mulatero, P., Monticone, S., Burrello, J., Veglio, F., Williams, T. A., & Funder, J. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001088 · Cited by 185
“The guidelines published by the Japan Endocrine Society in 2011 recommend screening all hypertensive patients for primary aldosteronism [4]; in the revised guidelines recently published by the Endocrine Society in 2016 [5], the previous recommendation has been expanded to 50% of hypertensive patients.”
BackgroundSelf-citationRenal damage in primary aldosteronism: a systematic review and meta-analysis
Monticone, S., Sconfienza, E., D’Ascenzo, F., Buffolo, F., Satoh, F., Sechi, L. A., Veglio, F., & Mulatero, P. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002216 · Cited by 173
“According with the currently available guidelines [29,30], unilateral adrenalectomy and medical therapy with mineralocorticoid receptor antagonists are the recommended treatments for primary aldosteronism.”
Kebebew, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2031112 · Cited by 198
CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism
Daniil, G., Fernandes-Rosa, F. L., Chemin, J., Blesneac, I., Beltrand, J., Polak, M., Jeunemaitre, X., Boulkroun, S., Amar, L., Strom, T. M., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.002 · Cited by 171
“…by hypertension, hypokalemia, and inadequate high levels of plasma aldosterone for low levels of terone producing adenoma; FH, ing. diovascular Research Center – Fernandes-Rosa), en access article under the CC BY-NC CNA1H Mutations Are Assoc 16.10.002 plasma renin (Funder et al., 2016).”
BackgroundInfluentialChinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 196
Primary Aldosteronism: Practical Approach to Diagnosis and Management
Byrd, J. B., Turcu, A. F., & Auchus, R. J. (2018) · Circulation · doi:10.1161/circulationaha.118.033597 · Cited by 169
Rossi, G. P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.057 · Cited by 165
Heinze, B., Fuss, C. T., Mulatero, P., Beuschlein, F., Reincke, M., Mustafa, M., Schirbel, A., Deutschbein, T., Williams, T. A., Rhayem, Y., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.09975 · Cited by 169
Self-citationWu, X., Senanayake, R., Goodchild, E., Bashari, W. A., Salsbury, J., Cabrera, C. P., Argentesi, G., O’Toole, S. M., Matson, M., Koo, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02114-5 · Cited by 148
Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study
Jaffe, G., Gray, Z., Krishnan, G., Stedman, M., Zheng, Y., Han, J., Chertow, G. M., Leppert, J. T., & Bhalla, V. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14359 · Cited by 163
“Biochemical testing with the plasma aldosterone-to-plasma renin activity ratio and identification of the subtype of primary aldosteronism are critical to provide appropriate treatment options.(15)”
BackgroundMethodInfluentialRossi, G. P., Bisogni, V., Rossitto, G., Maiolino, G., Cesari, M., Zhu, R., & Seccia, T. M. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00415-9 · Cited by 199
“MRAs are also indicated before adrenalectomy to control BP values and serum potassium levels [9, 27].”
BackgroundPathogenesis and treatment of primary aldosteronism
Zennaro, M., Boulkroun, S., & Fernandes-Rosa, F. L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0382-4 · Cited by 170
Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling
Rossi, G. P., Rossitto, G., Amar, L., Azizi, M., Riester, A., Reincke, M., Degenhart, C., Widimsky, J., Jr., Naruse, M., Deinum, J., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13463 · Cited by 168
“The possibility that in some cases adrenalectomy was based on the presence of AVS-biochemically determined contralateral adrenal aldosterone suppression cannot be ruled out, although the accuracy of this index for identification of unilateral PA(27) remains to be conclusively demonstrated.(11) With regard to adrenal i…”
BackgroundSelf-citationPrete, A., Subramanian, A., Bancos, I., Chortis, V., Tsagarakis, S., Lang, K., Macech, M., Delivanis, D. A., Pupovac, I. D., Reimondo, G., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-1737 · Cited by 154
“We excluded participants with confirmed primary aldosteronism diagnosed according to current guidelines (11) and participants with cortisol excess due to bilateral macronodular adrenal hyperplasia.”
BackgroundSelf-citationBurrello, J., Monticone, S., Losano, I., Cavaglià, G., Buffolo, F., Tetti, M., Covella, M., Rabbia, F., Veglio, F., Pasini, B., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14063 · Cited by 162
“Surprisingly, the prevalence of PA in patients with hypertension and hypokalemia is unknown.(8) The aim of our study was to investigate the prevalence of hypokalemia in patients referred to a tertiary hypertension unit and to identify the prevalence of PA in patients with hypokalemia.”
BackgroundMethodEvolution of the Primary Aldosteronism Syndrome: Updating the Approach
Vaidya, A., & Carey, R. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa606 · Cited by 158
Self-citationClinical guidelines for the management of adrenal incidentaloma
Lee, J.-M., Kim, M. K., Ko, S.-H., Koh, J.-M., Kim, B.-Y., Kim, S. W., Kim, S.-K., Kim, H. J., Ryu, O.-H., Park, J., et al. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.200 · Cited by 147
Secondary Hypertension: Discovering the Underlying Cause.
Charles, L. A., Triscott, J. A. C., & Dobbs, B. (2017) · PubMed · Cited by 226
Velema, M. S., Dekkers, T., Hermus, A. R., Timmers, H. J. L. M., Lenders, J. W. M., Groenewoud, H., Kool, L. J. S., Langenhuijsen, J. F., Prejbisz, A., van der Wilt, G. J., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01442 · Cited by 150
“However, it is impossible to obtain ethical approval for a randomized trial because ADX is generally accepted to be the preferred treatment of APA (43).”
InfluentialPrimary Aldosteronism: State-of-the-Art Review
Vaidya, A., Hundemer, G. L., Nanba, K., Parksook, W. W., & Brown, J. M. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac079 · Cited by 150
Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141
Rossi, G. P., Bisogni, V., Bacca, A., Belfiore, A., Cesari, M., Concistrè, A., Pinto, R. D., Fabris, B., Fallo, F., Fava, C., et al. (2020) · International Journal of Cardiology Hypertension · doi:10.1016/j.ijchy.2020.100029 · Cited by 147
Jing, Y., Hu, J., Luo, R., Mao, Y. J., Luo, Z., Zhang, M., Yang, J., Song, Y., Feng, Z., Wang, Z., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1619 · Cited by 157
Mulatero, P., Sechi, L. A., Williams, T. A., Lenders, J. W. M., Reincke, M., Satoh, F., Januszewicz, A., Naruse, M., Doumas, M. N., Veglio, F., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002520 · Cited by 147
“Imaging techniques display unacceptable sensitivity for the detection of micro-APAs (less than 10mm diameter) and low specificity for the distinction of APAs from nonsecretory adrenal adenomas as functional information is not provided [1].”
BackgroundSelf-citationGenetics of Primary Aldosteronism
Scholl, U. I. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.16498 · Cited by 153
“Somatic mutations cause abnormal permeability to Na+ or H+ and loss of pump function, leading to depolarization, aldosterone production and proliferation, likely via increased intracellular calcium and cellular acidification.17,18,20,21 Less frequently, plasma membrane Ca2+ ATPase (ATP2B3) mutations cause abnormal Na+…”
BackgroundInfluentialConfirmatory Tests for the Diagnosis of Primary Aldosteronism
Song, Y., Yang, S., He, W., Hu, J., Cheng, Q., Wang, Y., Luo, T., Ma, L., Zhen, Q., Zhang, S., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10197 · Cited by 132
Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism
Williams, T. A., Burrello, J., Sechi, L. A., Fardella, C., Matrozova, J., Adolf, C., Baudrand, R. F., Bernardi, S., Beuschlein, F., Catena, C., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11382 · Cited by 134
“Indeed, CT has been widely reported to be unreliable for differentiation of 60 unilateral from bilateral PA, lacks sensitivity for the detection of microadenomas ( 10 mm diameter) and specificity in patients with non-functional adrenal incidentalomas.6, 22-27 For these reasons AVS is recommended for the diagnostic wor…”
BackgroundMethodInfluentialSelf-citationSomatic CACNA1H Mutation As a Cause of Aldosterone-Producing Adenoma
Nanba, K., Blinder, A., Rege, J., Hattangady, N. G., Else, T., Liu, C., Tomlins, S. A., Vats, P., Kumar‐Sinha, C., Giordano, T. J., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14349 · Cited by 143
“The diagnosis of PA was made according to the institutional consensus available at the time or the Endocrine Society Clinical Practice guideline.(8) Patients for mutational analysis were selected based on the availability of archival FFPE blocks of”
MethodWilliams, T. A., & Reincke, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0990 · Cited by 141
Self-citationScreening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Young, W. F., Calhoun, D. A., Lenders, J. W. M., Stowasser, M., & Textor, S. C. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00054 · Cited by 144
“Given the known existence of familial forms, the guideline also recommends case detection for all hypertensive first-degree relatives of patients with PA (9).”
BackgroundInfluentialSelf-citationDiagnosis and treatment of arterial hypertension 2021
Ott, C., & Schmieder, R. E. (2021) · Kidney International · doi:10.1016/j.kint.2021.09.026 · Cited by 151
Hu, J., Xu, T., Shen, H., Song, Y., Yang, J., Zhang, A., Ding, H., Xing, N., Li, Z., Qiu, L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55609 · Cited by 130
Wu, V., Hu, Y., Er, L., Yen, R., Chang, C., Chang, Y., Lu, C., Chang, C., Lin, J., Lin, Y., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2017.06.004 · Cited by 127
Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization
Rossitto, G., Amar, L., Azizi, M., Riester, A., Reincke, M., Degenhart, C., Widimsky, J., Jr., Naruse, M., Deinum, J., SchultzeKool, L. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz017 · Cited by 132
“0,(11,14,15) in concert with SI cut-off definitions of 1.”
BackgroundMethodInfluentialSelf-citationBurrello, J., Burrello, A., Stowasser, M., Nishikawa, T., Quinkler, M. O., Prejbisz, A., Lenders, J. W. M., Satoh, F., Mulatero, P., Reincke, M., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003200 · Cited by 125
Self-citationEisenhofer, G., Durán, C., Cannistraci, C. V., Peitzsch, M., Williams, T. A., Riester, A., Burrello, J., Buffolo, F., Prejbisz, A., Beuschlein, F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.16209 · Cited by 131
“6 0 0 1 5 Diagnostic performancec Sensitivity, % 94 (93-94) 42 (40-45) 26 (24-29) 46 (42-49) 100 46 38 83 Specificity, % 69 (68-71) 89 (89-90) 94 (94-95) 97 (96-97) 85 92 93 98 AUROC 0.”
Self-citationHundemer, G. L., Imsirovic, H., Vaidya, A., Yozamp, N., Goupil, R., Madore, F., Agharazii, M., Knoll, G., & Sood, M. M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18118 · Cited by 121
Iñiguez-Ariza, N. M., Kohlenberg, J. D., Delivanis, D. A., Hartman, R. P., Dean, D. S., Thomas, M. A., Shah, M. Z., Herndon, J., McKenzie, T. J., Arlt, W., et al. (2018) · Mayo Clinic Proceedings: Innovations, Quality & Outcomes · doi:10.1016/j.mayocpiqo.2017.11.002 · Cited by 116
“Right 81 (38) 48 (40) 33 (34) Left 96 (44) 55 (47) 41 (42) Bilateral 39 (18) 15 (13) 24 (24)”
Self-citationYozamp, N. S., Hundemer, G. L., Moussa, M., Underhill, J., Fudim, T., Sacks, B. A., & Vaidya, A. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16429 · Cited by 129
“Systolic blood pressure at diagnosis, mm Hg 146 (21)”
Background(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Stowasser, M., Ahmed, A. H., Cowley, D., Wolley, M. J., Guo, Z., McWhinney, B. C., Ungerer, J. P. J., & Gordon, R. D. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01394 · Cited by 122
“diagnostic workup (including AVS) to determine the subtype (14).”
Self-citationImpaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion
Gerards, J., Heinrich, D. A., Adolf, C., Meisinger, C., Rathmann, W., Sturm, L., Nirschl, N., Bidlingmaier, M., Beuschlein, F., Thorand, B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00299 · Cited by 112
Self-citationParasiliti‐Caprino, M., Lopez, C., Prencipe, N., Lucatello, B. G., Settanni, F., Giraudo, G., Rossato, D., Mengozzi, G., Ghigo, E., Benso, A. S., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002441 · Cited by 120
“P rimary aldosteronism is a group of disorders caused by an excessive and autonomous aldosterone secretion [1] and is the most frequent form of secondary hypertension.”
BackgroundMethodImaging CXCR4 expression in patients with suspected primary hyperaldosteronism
Ding, J., Zhang, Y., Wen, J., Zhang, H., Wang, H., Luo, Y., Pan, Q., Zhu, W., Wang, X., Yao, S., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04722-0 · Cited by 111
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study
Hundemer, G. L., Agharazii, M., Madore, F., Vaidya, A., Brown, J. M., Leung, A. A. C., Kline, G. A., Larose, É., Piché, M., Crean, A. M., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.066389 · Cited by 112
“4 17 Rather, it has been proposed that PA spans a much broader continuum of renin-independent aldosteronism, wherein overt PA is merely the extreme end of the distribution.”
BackgroundGenetic Causes of Functional Adrenocortical Adenomas
Zennaro, M., Boulkroun, S., & Fernandes-Rosa, F. L. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00189 · Cited by 109
Genetics of Hypertension in African Americans and Others of African Descent
Zilbermint, M. F., Hannah‐Shmouni, F., & Stratakis, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051081 · Cited by 118
“The most frequent cause of primary aldosteronism is bilateral adrenal hyperplasia [81], often referred to as idiopathic adrenal hyperplasia.”
Background
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.